Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer-Reference-Cited by-同舟云学术

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer

Published:2021-12-04 Issue:3 Volume:11 Page:676-691
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Zhang Wenjing¹,Shi Fuyan¹,Kong Yujia¹,Li Yuting²,Sheng Chao³,Wang Suzhen¹,Wang Qinghua¹^ORCID

Affiliation:

1. Department of Health Statistics Key Laboratory of Medicine and Health of Shandong Province School of Public Health Weifang Medical University Weifang China

2. Tianjin Cancer Institute, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin Tianjin Medical University Cancer Institute and Hospital Tianjin China

3. Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin Medical University Cancer Institute and Hospital Tianjin China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4472

Reference66 articles.

1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

2. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer